Symbols / FLNA Stock $1.25 +4.17% Filana Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
FLNA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Richard Jon Barry
Exch · Country NCM · United States
Market Cap 60.38M
Enterprise Value -29.80M
Income -90.97M
Sales —
FCF (ttm) 20.22M
Book/sh 1.54
Cash/sh 1.98
Employees 17
Insider 10d —
IPO Jul 14, 2000
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E —
PEG 1.62
P/S —
P/B 0.81
P/C —
EV/EBITDA 0.50
EV/Sales —
Quick Ratio 2.18
Current Ratio 2.23
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.61
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -27.23%
ROE -82.66%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 48.31M
Shs Float 45.05M
Insider Own 11.02%
Instit Own 29.03%
Short Float 14.64%
Short Ratio 19.04
Short Interest 6.93M
52W High 4.98
vs 52W High -74.90%
52W Low 1.16
vs 52W Low 7.76%
Beta -0.76
Impl. Vol. 25.00%
Rel Volume 0.78
Avg Volume 502.07K
Volume 389.85K
Target (mean) $8.00
Tgt Median $8.00
Tgt Low $8.00
Tgt High $8.00
# Analysts 1
Recom Strong_buy
Prev Close $1.20
Price $1.25
Change 4.17%
About

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.00
Mean price target
2. Current target
$1.25
Latest analyst target
3. DCF / Fair value
$7.53
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.25
Low
$8.00
High
$8.00
Mean
$8.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-10-06 init LUCID CAPITAL MARKETS — → Buy $8
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-24 ANDERSON ROBERT EUGENE JR Director — 8,600 $2.90 $24,940
2025-11-20 BARRY RICHARD J Chief Executive Officer — 150,000 $2.76 $414,000
2025-11-19 BARRY RICHARD J Chief Executive Officer — 73,385 $2.75 $201,809
2025-09-30 COOK ROBERT CHRISTOPHER Chief Operating Officer — 13,725 $2.91 $39,940
2025-09-22 BARRY RICHARD J Chief Executive Officer — 7,172 $2.28 $16,352
2025-09-19 BARRY RICHARD J Chief Executive Officer — 237,941 $2.13 $534,743
2024-11-29 SCHOEN ERIC J. Chief Financial Officer — 50,000 $1.18 $59,000
2024-11-29 SCHOEN ERIC J. Chief Financial Officer — 61,800 $3.82 $238,468
2024-11-29 KUPIEC JAMES WILLIAM Officer — 4,000 $3.87 $15,480
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
96.13
-32.44%
142.28
+32.56%
107.33
+31.73%
81.48
Research And Development
26.59
-61.82%
69.64
-22.13%
89.42
+31.44%
68.03
Selling General And Administration
68.80
-4.19%
71.81
+334.31%
16.53
+37.92%
11.99
General And Administrative Expense
68.80
-4.19%
71.81
+334.31%
16.53
+37.92%
11.99
Other Gand A
68.80
-4.19%
71.81
+334.31%
16.53
+37.92%
11.99
Other Operating Expenses
0.74
-11.64%
0.83
-39.46%
1.38
-5.88%
1.46
Total Expenses
96.13
-32.44%
142.28
+32.56%
107.33
+31.73%
81.48
Operating Income
-96.13
+32.44%
-142.28
-32.56%
-107.33
-31.73%
-81.48
Total Operating Income As Reported
-95.39
+32.56%
-141.45
-33.49%
-105.96
-32.41%
-80.02
EBITDA
-95.19
+32.56%
-141.15
-33.41%
-105.80
-31.96%
-80.18
Normalized EBITDA
-95.19
+61.82%
-249.33
-135.65%
-105.80
-31.96%
-80.18
Reconciled Depreciation
0.94
-17.31%
1.13
-26.01%
1.53
+17.60%
1.30
EBIT
-96.13
+32.44%
-142.28
-32.56%
-107.33
-31.73%
-81.48
Total Unusual Items
—
108.18
—
0.00
Total Unusual Items Excluding Goodwill
—
108.18
—
0.00
Special Income Charges
—
—
—
0.00
Net Income
-90.97
-273.73%
-24.34
+74.96%
-97.22
-27.50%
-76.25
Pretax Income
-90.97
-273.73%
-24.34
+74.96%
-97.22
-27.50%
-76.25
Net Non Operating Interest Income Expense
4.62
-45.71%
8.51
+8.64%
7.83
+182.07%
2.78
Net Interest Income
4.62
-45.71%
8.51
+8.64%
7.83
+182.07%
2.78
Interest Income Non Operating
4.62
-45.71%
8.51
+8.64%
7.83
+182.07%
2.78
Interest Income
4.62
-45.71%
8.51
+8.64%
7.83
+182.07%
2.78
Other Income Expense
0.53
-99.51%
109.43
+4693.12%
2.28
-7.16%
2.46
Other Non Operating Income Expenses
0.53
-57.15%
1.24
-45.51%
2.28
-7.16%
2.46
Gain On Sale Of Security
—
108.18
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-90.97
-273.73%
-24.34
+74.96%
-97.22
-27.50%
-76.25
Net Income From Continuing Operation Net Minority Interest
-90.97
-273.73%
-24.34
+74.96%
-97.22
-27.50%
-76.25
Net Income From Continuing And Discontinued Operation
-90.97
-273.73%
-24.34
+74.96%
-97.22
-27.50%
-76.25
Net Income Continuous Operations
-90.97
-273.73%
-24.34
+74.96%
-97.22
-27.50%
-76.25
Normalized Income
-90.97
+31.35%
-132.53
-36.32%
-97.22
-27.50%
-76.25
Net Income Common Stockholders
-90.97
-273.73%
-24.34
+74.96%
-97.22
-27.50%
-76.25
Diluted EPS
-1.88
-28.77%
-1.46
+37.07%
-2.32
-22.11%
-1.90
Basic EPS
-1.88
-254.72%
-0.53
+77.16%
-2.32
-22.11%
-1.90
Basic Average Shares
48.30
+4.25%
46.33
+10.49%
41.93
+4.30%
40.20
Diluted Average Shares
48.30
+3.63%
46.60
+11.14%
41.93
+4.30%
40.20
Diluted NI Availto Com Stockholders
-90.97
-33.52%
-68.14
+29.91%
-97.22
-27.50%
-76.25
Average Dilution Earnings
0.00
+100.00%
-43.79
0.00
0.00
Gain On Sale Of PPE
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
118.36
-24.87%
157.53
+3.87%
151.66
-35.42%
234.83
Current Assets
97.71
-28.44%
136.53
+5.32%
129.63
-38.63%
211.23
Cash Cash Equivalents And Short Term Investments
95.50
-25.72%
128.57
+6.14%
121.14
-39.74%
201.01
Cash And Cash Equivalents
95.50
-25.72%
128.57
+6.14%
121.14
-39.74%
201.01
Receivables
0.12
-87.33%
0.95
-1.56%
0.96
0.00
Accrued Interest Receivable
0.12
-87.33%
0.95
-1.56%
0.96
0.00
Prepaid Assets
2.02
-70.99%
6.97
-3.79%
7.25
-27.89%
10.05
Other Current Assets
0.06
+68.42%
0.04
-86.76%
0.29
+79.38%
0.16
Total Non Current Assets
20.65
-1.69%
21.00
-4.67%
22.03
-6.68%
23.61
Net PPE
20.65
-1.69%
21.00
-3.90%
21.85
-4.92%
22.99
Gross PPE
24.79
+2.26%
24.24
+0.41%
24.14
-0.20%
24.19
Accumulated Depreciation
-4.14
-27.90%
-3.24
-41.68%
-2.28
-90.33%
-1.20
Properties
0.00
0.00
0.00
0.00
Land And Improvements
3.73
+0.00%
3.73
+0.00%
3.73
+0.00%
3.73
Buildings And Improvements
15.98
+0.00%
15.98
+0.00%
15.98
-0.76%
16.10
Machinery Furniture Equipment
0.89
+1.83%
0.88
+0.81%
0.87
+2.00%
0.85
Construction In Progress
0.03
-54.55%
0.06
0.00
-100.00%
0.01
Other Properties
0.69
+29.38%
0.53
+7.49%
0.49
+5.11%
0.47
Leases
3.47
+13.26%
3.06
+0.00%
3.06
+1.53%
3.02
Goodwill And Other Intangible Assets
—
0.04
-78.98%
0.18
-71.70%
0.62
Other Intangible Assets
—
0.04
-78.98%
0.18
-71.70%
0.62
Other Non Current Assets
—
—
—
—
Total Liabilities Net Minority Interest
43.95
+271.56%
11.83
-16.67%
14.20
+94.59%
7.29
Current Liabilities
43.83
+273.06%
11.75
-17.22%
14.20
+100.98%
7.06
Payables And Accrued Expenses
42.01
+316.20%
10.09
-25.83%
13.61
+116.13%
6.30
Payables
41.65
+444.12%
7.65
-27.61%
10.57
+163.21%
4.02
Accounts Payable
41.65
+444.12%
7.65
-27.61%
10.57
+163.21%
4.02
Current Accrued Expenses
0.36
-85.08%
2.44
-19.66%
3.04
+33.20%
2.28
Pensionand Other Post Retirement Benefit Plans Current
1.62
+19.75%
1.36
+578.50%
0.20
+17.65%
0.17
Current Debt And Capital Lease Obligation
—
—
—
0.10
Current Capital Lease Obligation
—
—
0.00
-100.00%
0.10
Other Current Liabilities
0.20
-33.78%
0.30
-22.34%
0.39
-21.75%
0.49
Total Non Current Liabilities Net Minority Interest
0.12
+49.37%
0.08
0.00
-100.00%
0.23
Long Term Debt And Capital Lease Obligation
—
—
0.00
-100.00%
0.04
Long Term Capital Lease Obligation
—
—
0.00
-100.00%
0.04
Other Non Current Liabilities
0.12
+49.37%
0.08
—
0.20
Stockholders Equity
74.40
-48.94%
145.70
+5.99%
137.47
-39.58%
227.54
Common Stock Equity
74.40
-48.94%
145.70
+5.99%
137.47
-39.58%
227.54
Capital Stock
0.05
+0.00%
0.05
+14.29%
0.04
+0.00%
0.04
Common Stock
0.05
+0.00%
0.05
+14.29%
0.04
+0.00%
0.04
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
48.31
+0.22%
48.20
+14.13%
42.24
+1.20%
41.74
Ordinary Shares Number
48.31
+0.22%
48.20
+14.13%
42.24
+1.20%
41.74
Additional Paid In Capital
570.44
+3.57%
550.77
+6.29%
518.20
+1.40%
511.05
Retained Earnings
-496.08
-22.46%
-405.11
-6.39%
-380.77
-34.29%
-283.55
Total Equity Gross Minority Interest
74.40
-48.94%
145.70
+5.99%
137.47
-39.58%
227.54
Total Capitalization
74.40
-48.94%
145.70
+5.99%
137.47
-39.58%
227.54
Working Capital
53.88
-56.82%
124.78
+8.09%
115.44
-43.46%
204.16
Invested Capital
74.40
-48.94%
145.70
+5.99%
137.47
-39.58%
227.54
Total Debt
—
—
0.00
-100.00%
0.14
Capital Lease Obligations
—
—
0.00
-100.00%
0.14
Net Tangible Assets
74.40
-48.94%
145.70
+6.13%
137.29
-39.50%
226.92
Tangible Book Value
74.40
-48.94%
145.70
+6.13%
137.29
-39.50%
226.92
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-32.25
+72.42%
-116.93
-42.55%
-82.03
-5.82%
-77.51
Cash Flow From Continuing Operating Activities
-32.25
+72.42%
-116.93
-42.55%
-82.03
-5.82%
-77.51
Net Income From Continuing Operations
-90.97
-273.73%
-24.34
+74.96%
-97.22
-27.50%
-76.25
Depreciation Amortization Depletion
0.94
-17.31%
1.13
-26.01%
1.53
+17.60%
1.30
Depreciation
0.90
-5.15%
0.95
-12.18%
1.08
+34.83%
0.80
Amortization Cash Flow
0.03
-81.67%
0.18
-59.64%
0.45
-10.26%
0.50
Depreciation And Amortization
0.94
-17.31%
1.13
-26.01%
1.53
+17.60%
1.30
Amortization Of Intangibles
0.03
-81.67%
0.18
-59.64%
0.45
-10.26%
0.50
Stock Based Compensation
19.58
+20.20%
16.29
+255.23%
4.59
+121.97%
2.07
Operating Gains Losses
—
-108.18
—
—
Gain Loss On Investment Securities
—
-108.18
—
—
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
38.20
+2191.02%
-1.83
-120.13%
9.08
+295.81%
-4.63
Change In Prepaid Assets
6.08
+1028.01%
0.54
-68.55%
1.71
+44.15%
1.19
Change In Payables And Accrued Expense
31.92
+1007.76%
-3.52
-145.94%
7.65
+292.67%
-3.97
Change In Accrued Expense
-2.08
-247.74%
-0.60
-178.86%
0.76
+244.74%
-0.52
Change In Payable
33.99
+1264.54%
-2.92
-142.33%
6.90
+299.94%
-3.45
Change In Account Payable
33.99
+1264.54%
-2.92
-142.33%
6.90
+299.94%
-3.45
Change In Other Working Capital
0.27
-76.84%
1.16
+8800.00%
0.01
+100.76%
-1.72
Change In Other Current Liabilities
-0.06
-785.71%
-0.01
+97.70%
-0.30
-123.53%
-0.14
Investing Cash Flow
-0.58
-464.08%
-0.10
+75.12%
-0.41
+84.73%
-2.71
Cash Flow From Continuing Investing Activities
-0.58
-464.08%
-0.10
+75.12%
-0.41
+84.73%
-2.71
Net PPE Purchase And Sale
-0.58
-464.08%
-0.10
+75.12%
-0.41
+84.73%
-2.71
Purchase Of PPE
-0.58
-464.08%
-0.10
+75.12%
-0.41
+84.73%
-2.71
Sale Of PPE
—
—
—
0.00
Capital Expenditure
-0.58
-464.08%
-0.10
+75.12%
-0.41
+84.73%
-2.71
Financing Cash Flow
-0.24
-100.19%
124.47
+4762.11%
2.56
-94.64%
47.80
Cash Flow From Continuing Financing Activities
-0.24
-100.19%
124.47
+4762.11%
2.56
-94.64%
47.80
Net Common Stock Issuance
—
0.00
0.00
-100.00%
47.33
Proceeds From Stock Option Exercised
0.09
-99.93%
124.47
+4762.11%
2.56
+438.95%
0.47
Net Other Financing Charges
-0.33
—
—
—
Changes In Cash
-33.07
-544.64%
7.44
+109.31%
-79.88
-146.37%
-32.42
Beginning Cash Position
128.57
+6.14%
121.14
-39.74%
201.01
-13.89%
233.44
End Cash Position
95.50
-25.72%
128.57
+6.14%
121.14
-39.74%
201.01
Free Cash Flow
-32.83
+71.95%
-117.03
-41.96%
-82.44
-2.76%
-80.23
Common Stock Issuance
—
0.00
0.00
-100.00%
47.33
Issuance Of Capital Stock
—
0.00
0.00
-100.00%
47.33
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category